Richard C. Dodel
#165,917
Most Influential Person Now
Richard C. Dodel's AcademicInfluence.com Rankings
Richard C. Dodelphilosophy Degrees
Philosophy
#9765
World Rank
#13371
Historical Rank
Logic
#6724
World Rank
#8269
Historical Rank
Richard C. Dodelbiology Degrees
Biology
#13444
World Rank
#16989
Historical Rank
Neuroscience
#2330
World Rank
#2394
Historical Rank
Download Badge
Philosophy Biology
Richard C. Dodel's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Neuroscience University of California, San Francisco
Why Is Richard C. Dodel Influential?
(Suggest an Edit or Addition)Richard C. Dodel's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
- Cost of disorders of the brain in Europe 2010 (2011) (1341)
- Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria (2017) (1150)
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
- Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease (2001) (772)
- Prevalence and incidence of Parkinson's disease in Europe (2005) (608)
- Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition (1997) (583)
- Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. (1999) (479)
- The natural history of multiple system atrophy: a prospective European cohort study (2013) (376)
- Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease (2004) (350)
- Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. (1997) (341)
- Activation of a caspase 3-related cysteine protease is required for glutamate-mediated apoptosis of cultured cerebellar granule neurons. (1997) (278)
- Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment (2004) (268)
- Cognitive impairment in 873 patients with idiopathic Parkinson's disease (2008) (260)
- Long-Term Outcome After Stroke: Evaluating Health-Related Quality of Life Using Utility Measurements (2006) (255)
- IFATS Collection: The Conditioned Media of Adipose Stromal Cells Protect Against Hypoxia‐Ischemia‐Induced Brain Damage in Neonatal Rats (2009) (241)
- Reduced levels of amyloid β-peptide antibody in Alzheimer disease (2001) (231)
- Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease (2010) (227)
- Activation mapping in essential tremor with functional magnetic resonance imaging (1997) (222)
- The future of Alzheimer's disease: The next 10 years (2011) (203)
- Red flags for multiple system atrophy (2008) (198)
- Long-Term Outcome After Stroke Evaluating Health-Related Quality of Life Using Utility Measurement (2006) (195)
- Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument (2008) (192)
- Association of an interleukin 1α polymorphism with Alzheimer’s disease (2000) (185)
- Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease (2002) (181)
- Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial (2013) (178)
- The NF-κB/Rel family of proteins mediates Aβ-induced neurotoxicity and glial activation (1998) (173)
- Involvement of a Caspase‐3‐Like Cysteine Protease in 1‐Methyl‐4‐Phenylpyridinium‐Mediated Apoptosis of Cultured Cerebellar Granule Neurons (1997) (160)
- Rate of clinical progression in Parkinson's disease. A prospective study (2007) (159)
- Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. (2004) (158)
- Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) (2010) (155)
- Projected numbers of people with movement disorders in the years 2030 and 2050 (2011) (143)
- Health-Related Quality of Life in patients with Parkinson's disease—A systematic review based on the ICF model (2016) (141)
- Affective and cognitive Theory of Mind in patients with parkinson's disease. (2010) (137)
- Health-related quality of life in patients with narcolepsy. (2007) (136)
- Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons (2001) (134)
- The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings. (2013) (132)
- α2‐Macroglobulin as a β‐Amyloid Peptide‐Binding Plasma Protein (1997) (131)
- Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease (2013) (130)
- Human anti‐β‐amyloid antibodies block β‐amyloid fibril formation and prevent β‐amyloid‐induced neurotoxicity (2003) (130)
- Cost of Epilepsy (2012) (127)
- Cost of illness and its predictors for Parkinson’s disease in Germany (2012) (123)
- Cost of epilepsy: a systematic review. (2008) (120)
- Assessing health-related quality of life in patients with restless legs syndrome. (2009) (119)
- Caspase-3-like proteases and 6-hydroxydopamine induced neuronal cell death. (1999) (119)
- Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease (2010) (119)
- Naturally Occurring Autoantibodies against β-Amyloid: Investigating Their Role in Transgenic Animal and In Vitro Models of Alzheimer's Disease (2011) (118)
- Role of MIF in Inflammation and Tumorigenesis (2008) (114)
- α2‐Macroglobulin Attenuates β‐Amyloid Peptide 1–40 Fibril Formation and Associated Neurotoxicity of Cultured Fetal Rat Cortical Neurons (1998) (110)
- Theory of mind in Parkinson's disease and related basal ganglia disorders: A systematic review (2010) (109)
- Which ante mortem clinical features predict progressive supranuclear palsy pathology? (2017) (108)
- Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany—a nationwide population-based study in children and adults (2012) (108)
- Sodium Salicylate and 17β‐Estradiol Attenuate Nuclear Transcription Factor NF‐κB Translocation in Cultured Rat Astroglial Cultures Following Exposure to Amyloid Aβ1‐40 and Lipoplysaccharides (1999) (106)
- Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study. (2007) (106)
- Direct and Indirect Costs of Refractory Epilepsy in a Tertiary Epilepsy Center in Germany (2006) (102)
- Costs of epilepsy and cost‐driving factors in children, adolescents, and their caregivers in Germany (2015) (101)
- Health‐related quality of life in patients with Gilles de la Tourette's syndrome (2010) (99)
- Caregiver Burden in Alzheimer's Disease: Differential Associations in Adult-Child and Spousal Caregivers in the GERAS Observational Study (2014) (97)
- The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity (2005) (95)
- Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease (2013) (93)
- Costs of illness and care in Parkinson's Disease: An evaluation in six countries (2011) (92)
- The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors (2009) (89)
- Cost‐effectiveness of deep brain stimulation in patients with Parkinson's disease (2013) (87)
- Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus (2002) (86)
- A Consensus Set of Outcomes for Parkinson’s Disease from the International Consortium for Health Outcomes Measurement (2017) (85)
- Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury. (2004) (84)
- Costs of drug treatment in Parkinson's disease (1998) (84)
- Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. (2000) (83)
- Resource utilization and costs of stroke unit care in Germany. (2004) (80)
- Minocycline prevents gentamicin-induced ototoxicity by inhibiting p38 MAP kinase phosphorylation and caspase 3 activation (2005) (80)
- Evaluation of health-care utilization among adult patients with epilepsy in Germany (2012) (78)
- Evaluation of costs and outcome in cardioembolic stroke or TIA (2009) (78)
- Occurrence Risk and Structure of Depression in Parkinson Disease With and Without Dementia: Results From the GEPAD Study (2010) (77)
- CSF cortisol in Alzheimer's disease and mild cognitive impairment (2009) (77)
- Economic Evaluation of Treatment Options in Patients with Alzheimer’s Disease (2012) (77)
- The Role of Macrophage Migration Inhibitory Factor in Alzheimer’s Disease (2010) (75)
- The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. (1998) (74)
- Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy (2010) (74)
- The socioeconomic impact of narcolepsy. (2004) (73)
- Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort study. (2011) (73)
- Cost of Parkinson's disease in Europe (2005) (73)
- Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy (2009) (73)
- Analysis of burden in caregivers of people with Alzheimer’s disease using self-report and supervision hours (2014) (73)
- Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. (2009) (73)
- Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study (2016) (73)
- Health-Related Quality of Life in Patients with Subarachnoid Haemorrhage (2010) (72)
- Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. (2003) (72)
- Costs of Parkinson's disease in eastern Europe: a Czech cohort study. (2010) (72)
- Incidence of Parkinson's disease and atypical parkinsonism: Russian population‐based study (2010) (71)
- Costs and cost‐driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany (2016) (70)
- Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide (2005) (69)
- Peptide inhibitors of caspase-3-like proteases attenuate MPP+ -induced toxicity of cultured fetal rat mesencephalic dopamine neurons (1998) (68)
- Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study (2010) (68)
- Caffeic acid phenethyl ester prevents cerebellar granule neurons (CGNs) against glutamate-induced neurotoxicity (2008) (68)
- Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. (2008) (67)
- Determinants of societal costs in Alzheimer's disease: GERAS study baseline results (2015) (66)
- Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. (2001) (66)
- α2 Macroglobulin and the risk of Alzheimer’s disease (2000) (63)
- Immunotherapy for Alzheimer's disease (2003) (62)
- Social and clinical determinants of quality of life in Parkinson’s disease in Austria: a cohort study (2010) (62)
- Cost of Illness in Subarachnoid Hemorrhage: A German Longitudinal Study (2010) (62)
- Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. (2003) (61)
- Comparative responsiveness of Parkinson's disease scales to change over time (2009) (61)
- The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. (1998) (60)
- A multicentre RCT on community occupational therapy in Alzheimer's disease: 10 sessions are not better than one consultation (2011) (60)
- Comparing the neural correlates of affective and cognitive theory of mind using fMRI: Involvement of the basal ganglia in affective theory of mind (2013) (59)
- Sodium salicylate and 17beta-estradiol attenuate nuclear transcription factor NF-kappaB translocation in cultured rat astroglial cultures following exposure to amyloid A beta(1-40) and lipopolysaccharides. (1999) (59)
- Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany (2013) (53)
- Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease (2012) (53)
- Antibody-based therapy in Alzheimer's disease (2011) (53)
- Psychiatric symptoms in Parkinson’s disease (2008) (52)
- The α7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice. (2013) (52)
- Longitudinal study of the socioeconomic burden of Parkinson’s disease in Germany (2010) (52)
- Costs of acute stroke care on regular neurological wards: a comparison with stroke unit setting. (2007) (51)
- Who was the man who discovered the “Lewy bodies”? (2010) (51)
- Social and clinical determinants of quality of life in Parkinson's disease in a Russian cohort study. (2010) (51)
- Effect of minocycline in experimental autoimmune encephalomyelitis (2002) (51)
- Pharmacotherapy of Parkinson’s disease in Germany (2005) (50)
- Health-Related Quality of Life in Multiple System Atrophy and Progressive Supranuclear Palsy (2011) (50)
- Lewy body dementia and Parkinson’s disease with dementia (2008) (49)
- Caffeic acid phenethyl ester prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration (2011) (49)
- Frequency and treatment of depressive symptoms in a Parkinson's disease registry. (2008) (49)
- alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein. (1997) (46)
- Cognitive decline in Parkinson’s disease: the impact of the motor phenotype on cognition (2018) (45)
- What determines health-related quality of life in hip fracture patients at the end of acute care?—a prospective observational study (2014) (45)
- Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings. (2011) (44)
- RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels (2010) (44)
- Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson’s Disease (2012) (44)
- Biomarkers of Parkinson's disease and Dementia with Lewy bodies (2011) (43)
- Pathogenic and physiological autoantibodies in the central nervous system (2012) (43)
- Activation of KCNN3/SK3/KCa2.3 channels attenuates enhanced calcium influx and inflammatory cytokine production in activated microglia (2012) (42)
- Improve hip fracture outcome in the elderly patient (iHOPE): a study protocol for a pragmatic, multicentre randomised controlled trial to test the efficacy of spinal versus general anaesthesia (2018) (41)
- Parkinson’s Disease and Dementia: A Longitudinal Study (DEMPARK) (2011) (41)
- Factors influencing the progress of mobilization in hip fracture patients during the early postsurgical period?-A prospective observational study. (2015) (41)
- Immunotherapy in prion disease (2013) (41)
- Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamine-induced neurotoxicity. (2006) (41)
- The Economic Impact of Parkinson’s Disease (1998) (40)
- Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson’s Disease (2015) (39)
- Successful treatment of sexual disinhibition in dementia with carbamazepine -- a case report. (2005) (39)
- Cost‐effectiveness of neurostimulation in Parkinson's disease with early motor complications (2016) (35)
- Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. (1998) (35)
- Dopamine transporter imaging and SPECT in diagnostic work‐up of Parkinson's disease: A decision‐analytic approach (2003) (35)
- Costs of Illness in a Russian Cohort of Patients with Parkinson’s Disease (2012) (34)
- Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells (2011) (34)
- Pallidal lesions. Structural and functional magnetic resonance imaging. (1996) (34)
- Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease (2014) (33)
- α1-antitrypsin modulates microglial-mediated neuroinflammation and protects microglial cells from amyloid-β-induced toxicity (2014) (33)
- Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease (2003) (33)
- Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease (2015) (32)
- Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes (2017) (32)
- Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4-phenylpyridinum-induced toxicity of cultured fetal rat mesencephalic dopamine neurons. (1998) (32)
- Prodromal Markers in Parkinson’s Disease: Limitations in Longitudinal Studies and Lessons Learned (2016) (31)
- Naturally occurring autoantibodies against β-Amyloid. (2012) (31)
- Economic Burden in a German Cohort of Patients with Multiple Sclerosis (2011) (31)
- Costs of Parkinson’s Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study (2010) (31)
- Health Economic Burden of Patients with Restless Legs Syndrome in a German Ambulatory Setting (2012) (30)
- Activation of SK2 channels preserves ER Ca2+ homeostasis and protects against ER stress-induced cell death (2015) (30)
- Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment (2013) (30)
- Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning (2017) (30)
- Widespread microglial activation in multiple system atrophy (2019) (29)
- How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer’s disease? (2017) (29)
- Depression and care-dependency in Parkinson's disease: results from a nationwide study of 1449 outpatients. (2012) (29)
- SK channel activation modulates mitochondrial respiration and attenuates neuronal HT-22 cell damage induced by H2O2 (2015) (28)
- Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. (2017) (28)
- Pre-fracture quality of life predicts 1-year survival in elderly patients with hip fracture—development of a new scoring system (2016) (28)
- Trends in resource utilization for Parkinson's disease in Germany (2010) (28)
- Re-admission to Level 2 unit after hip-fracture surgery - Risk factors, reasons and outcome. (2013) (28)
- Factors associated with long-term impact on informal caregivers during Alzheimer’s disease dementia progression: 36-month results from GERAS (2019) (28)
- An Interleukin-6 Promoter Variant Is Not Associated with an Increased Risk for Alzheimer’s Disease (2004) (27)
- Health-Related Quality of Life in Patients with Alzheimer's Disease in Different German Health Care Settings. (2016) (26)
- Association of Clusterin Gene Polymorphisms with Late-Onset Alzheimer’s Disease (2011) (26)
- Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease (2008) (26)
- Effect of Preexisting Cognitive Impairment on In-Patient Treatment and Discharge Management among Elderly Patients with Hip Fractures (2015) (26)
- Health-related quality of life and economic burden in patients with restless legs syndrome (2007) (26)
- Centenary of Lewy bodies (1912–2012) (2013) (26)
- Lack of association between the interleukin-1 alpha (−889) polymorphism and early-onset Parkinson's disease (2004) (25)
- Human Anti-prion Antibodies Block Prion Peptide Fibril Formation and Neurotoxicity (2012) (25)
- Preference-based Health status in a German outpatient cohort with multiple sclerosis (2013) (25)
- How pain empathy depends on ingroup/outgroup decisions: A functional magnet resonance imaging study (2015) (25)
- Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta. (2010) (25)
- A polymorphism in the cystatin C promoter region is not associated with an increased risk of AD. (2002) (25)
- CNI-1493 inhibits Aβ production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease (2008) (25)
- Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease - Report of the JPND Working Group BioLoC-PD (2015) (24)
- Systematic assessment of decision models in Parkinson's disease. (2004) (24)
- Alpha2 macroglobulin and the risk of Alzheimer's disease. (2000) (23)
- Macrophage Migration Inhibitory Factor in Normal Human Skeletal Muscle and Inflammatory Myopathies (2010) (23)
- Cost Effectiveness of Pharmacotherapies in Early Parkinson’s Disease (2008) (23)
- IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target? (2019) (23)
- Differently selected D-enantiomeric peptides act on different Abeta species. (2010) (22)
- Cost of illness in patients with Gilles de la Tourette’s syndrome (2010) (22)
- What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study. (2017) (22)
- Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia (2013) (22)
- Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study (2018) (22)
- Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease (2011) (22)
- The role of CNI-1493 in the function of primary microglia with respect to amyloid-β. (2011) (22)
- Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease. (2016) (21)
- Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer’s disease dementia (2018) (21)
- Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown (2009) (21)
- Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's disease (2012) (20)
- The role of choroid plexus in IVIG-induced beta-amyloid clearance (2014) (20)
- APP transgenic mice: The effect of active and passive immunotherapy in cognitive tasks (2010) (20)
- Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation (2010) (19)
- Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia (2016) (19)
- [Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs]. (1997) (19)
- International guide to drugs for Parkinson's disease (1995) (19)
- Health-Related Quality of Life in Patients with a History of Myocardial Infarction and Stroke (2010) (18)
- The endogenous α7 nicotinic acetylcholine receptor antagonist kynurenic acid modulates amyloid-β-induced inflammation in BV-2 microglial cells (2014) (18)
- Longitudinal brain atrophy distribution in advanced Parkinson's disease: What makes the difference in “cognitive status” converters? (2019) (18)
- Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease (2014) (18)
- Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases (2011) (18)
- Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease (2009) (17)
- Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson’s disease (2013) (17)
- NF-κB mediates IL-1β-induced synthesis/release of α2-macroglobulin in a human glial cell line (2002) (17)
- Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation (2007) (17)
- Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson’s Disease: Sources of (Error) Variance in Biomarker Assays (2014) (17)
- Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease (2012) (16)
- Characteristics of Patients with Late-Stage Parkinsonism who are Nursing Home Residents Compared with those Living at Home. (2020) (16)
- Cabergoline versus levodopa monotherapy: A decision analysis (2003) (16)
- Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data (2016) (16)
- Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. (2011) (16)
- Prevalence, Duration and Severity of Parkinson's Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples (2017) (16)
- Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies (2016) (16)
- Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood (2018) (15)
- Rapid detection of a pentanucleotide deletion polymorphism in the human alpha2-macroglobulin gene. (1999) (15)
- Awareness and Knowledge of the Clinical Practice Guideline on Parkinson’s Disease among German Neurologists (2009) (15)
- Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. (2018) (15)
- How to deal with missing longitudinal data in cost of illness analysis in Alzheimer’s disease—suggestions from the GERAS observational study (2016) (15)
- Trajectory classes of decline in health-related quality of life in Parkinson's disease: a pilot study. (2011) (15)
- Mitochondrial changes in muscle phosphoglycerate kinase deficiency. (1996) (15)
- The Prevalence and Determinants of Neuropsychiatric Symptoms in Late‐Stage Parkinsonism (2020) (15)
- [Direct costs for Parkinson's treatment in private neurology practices in Berlin]. (2009) (15)
- Health-Related Quality of Life and its Determinants in the Urban Russian Population with Major Depressive Disorder: A Cross-Sectional Study (2012) (14)
- [Cost of illness and health service patterns in Morbus Parkinson in Austria]. (2009) (14)
- Bupropion for the Treatment of Apathy in Alzheimer Disease (2020) (14)
- Costs of epilepsy and their predictors: Cross-sectional study in Germany and review of literature (2013) (14)
- Analysis of burden in caregivers of people with Alzheimer’s disease using self-report and supervision hours (2014) (14)
- [Parkinson's disease: cost-of-illness in an outpatient cohort]. (2011) (14)
- Structural brain signature of cognitive decline in Parkinson’s disease: DTI-based evidence from the LANDSCAPE study (2019) (14)
- TREM2 rare variant p.R47H is not associated with Parkinson's disease. (2016) (14)
- Quality of life in a German cohort of Parkinson’s patients assessed with three different measures (2018) (14)
- [Long-term disease-related costs 4 years after stroke or TIA in Germany]. (2008) (14)
- α2-Macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease (2006) (14)
- [Anticoagulation medication for proximal femoral fractures: prospective validation study of new institutional guidelines]. (2013) (13)
- Predictors of noninstitutionalized survival 1 year after hip fracture (2017) (13)
- C/T conversion alters interleukin-1A promoter function in a human astrocyte cell line. (2007) (13)
- Diagnosis and treatment of cognitive impairment (2019) (13)
- Structural and Functional Magnetic Resonance Imaging (2017) (13)
- Synthetic Dimeric Aβ(28–40) Mimics the Complex Epitope of Human Anti-Aβ Autoantibodies against Toxic Aβ Oligomers* (2013) (13)
- Health outcome of older hospitalized patients in internal medicine environments evaluated by Identification of Seniors at Risk (ISAR) screening and geriatric assessment (2019) (13)
- Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany (2018) (12)
- Treatment of Odontoid Type II Fractures in Octogenarians: Balancing Two Different Treatment Strategies (2019) (12)
- Corrigendum to “Cost of disorders of the brain in Europe 2010” [Eur. Neuropsychopharmacol. 21 (2011) 718–779] (2012) (12)
- The neuroprotective role of microglial cells against amyloid beta‐mediated toxicity in organotypic hippocampal slice cultures (2019) (12)
- Reduction of glutamate-induced excitotoxicity in murine primary neurons involving calpain inhibition (2015) (12)
- Immune checkpoint inhibitor-associated CNS autoimmune disorder (ICICAD) following nivolumab treatment: A new entity of drug-induced autoimmune encephalitis? (2017) (12)
- Prescription of Benzodiazepines and Related Drugs in Patients with Mild Cognitive Deficits and Alzheimer’s Disease (2018) (11)
- Factors Associated with Health‐Related Quality of Life in Late‐Stage Parkinson's Disease (2021) (11)
- Evaluation of the Obesity Genes FTO and MC4R and the Type 2 Diabetes Mellitus Gene TCF7L2 for Contribution to Stroke Risk: The Mannheim-Heidelberg Stroke Study (2011) (11)
- Prion Peptide Uptake in Microglial Cells – The Effect of Naturally Occurring Autoantibodies against Prion Protein (2013) (11)
- Cerebrotendinous xanthomatosis: A treatable ataxia (2005) (11)
- [Costs of stroke unit care in Germany. Resource use and reimbursements by German diagnosis related groups]. (2004) (11)
- Caregiver Burden in Late-Stage Parkinsonism and Its Associations (2020) (11)
- [Therapy of Alzheimer's disease: current status and future development]. (2008) (11)
- No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors (2019) (10)
- Interpreting Health Economics Data in Parkinson's Disease (2011) (10)
- Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time (2012) (10)
- Costs of Treating Dystonias and Hemifacial Spasm with Botulinum Toxin A (1997) (10)
- Trial of Deferiprone in Parkinson's Disease. (2022) (10)
- Neurogeriatrics—a vision for improved care and research for geriatric patients with predominating neurological disabilities (2020) (10)
- Synthesis of a biological active β-hairpin peptide by addition of two structural motifs. (2017) (9)
- Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease. (2006) (9)
- Antipsychotic treatment of community-dwelling and institutionalised patients with dementia in Germany (2018) (9)
- Cost-of-illness in multiple system atrophy and progressive supranuclear palsy (2011) (9)
- Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease (2017) (9)
- Dementia in Parkinson ’ s disease Author : Doctor (2004) (9)
- Clinical and functional patient characteristics predict medical needs in older patients at risk of functional decline (2019) (8)
- Increased KCNJ18 promoter activity as a mechanism in atypical normokalemic periodic paralysis (2018) (8)
- Immunization as treatment for Parkinson's disease. (2009) (8)
- Role of dopamine transporter SPECT for the practitioner and the general neurologist (2003) (8)
- Copper deficiency associated with severe neurological disorder — A genetic work-up of possible mutations in copper transport proteins (2010) (8)
- In vivo markers of Parkinson’s disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody (2014) (8)
- [Depression in Parkinson's disease. Assessment and treatment]. (2007) (8)
- [The German Study on the Epidemiology of Parkinson's Disease with Dementia (GEPAD): more than Parkinson]. (2010) (7)
- Treatment of hypersexuality in Parkinson's disease with carbamazepine—A case report (2009) (7)
- Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study (2021) (7)
- Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein (2018) (7)
- [Dementia and depression determine care dependency in Parkinson's disease: analysis of 1,449 outpatients receiving nursing care in Germany]. (2011) (7)
- Association between longitudinal clinical outcomes in patients with hip fracture and their pre‐fracture place of residence (2020) (7)
- NF-kappaB mediates IL-1beta-induced synthesis/release of alpha2-macroglobulin in a human glial cell line. (2002) (7)
- Is treatment of geriatric hip fracture patients cost-covering? Results of a prospective study conducted at a German University Hospital (2018) (6)
- [Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy]. (1996) (6)
- Advances in the development of antibody-based immunotherapy against prion disease (2014) (6)
- Depression bei M. Parkinson (2007) (6)
- Clinical and Pharmacological Properties of New Oral Anticoagulants for the Prevention of Cerebral Thromboembolism: Factor Xa and Thrombin Inhibitors (2012) (5)
- Assessment of cognitive impairment and related risk factors in hemodialysis patients (2021) (5)
- The socioeconomic impact of narcolepsy. Sleep 27, 1123-8 (2004) (5)
- Encoding the Sequence of Specific Autoantibodies Against beta-Amyloid and alpha-Synuclein in Neurodegenerative Diseases (2019) (5)
- Is there underfunding in brain research? The UK research expenditure (2012) (5)
- [Health-economic burden of Parkinson's disease in Portugal: a cohort study]. (2011) (5)
- Effect of naturally occurring α-synuclein-antibodies on toxic α-synuclein-fragments (2019) (5)
- An economic evaluation of deep brain stimulation for patients with Parkinson's disease (2016) (5)
- Subjective cognitive decline in idiopathic Parkinson´s disease: A systematic review (2021) (5)
- A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10-04) (2011) (5)
- Early signs of VCP-related frontotemporal dementia: a neuropsychological, FDG-PET and fMRI study (2011) (5)
- Brain age and Alzheimer's-like atrophy are domain-specific predictors of cognitive impairment in Parkinson's disease (2021) (5)
- The economic benefit of timely, adequate, and adherence to Parkinson's disease treatment: the Value of Treatment Project 2 (2020) (5)
- Mapping the EQ-5 D index by UPDRS and PDQ-8 in patients with Parkinson ’ s disease (2013) (4)
- QL2 Evaluation of Minimal Clinically Important Differences for Health-Related Quality of Life Scales in Parkinson'S Disease (2012) (4)
- Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson's Disease. (2022) (4)
- Comparing Resource Use In Alzheimer's Disease Across Three European Countries - 18-Month Results of The Geras Study. (2015) (4)
- [Multimorbidity: concept, epidemiology and treatment]. (2014) (4)
- Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. (2020) (4)
- The Economic Burden of Parkinson's Disease (2008) (4)
- Standard set measuring patient-centred outcomes in Parkinson's disease : an international, cross-disciplinary effort (2015) (4)
- Evaluating the Murine Anti-Human Antibody Response and Assessment of General Activity and Cognition after Treatment with Human Intravenous Immunoglobulins in Healthy Adult C57/B6J Mice (2014) (4)
- VV6 TRANSFORMING THE UNIFIED PARKINSON'S DISEASE RATING SCALE INTO A UTILITY SCALE (2003) (3)
- Revised clinical diagnostic criteria for progressive supranuclear palsy (PSP) (2016) (3)
- A novel V272D presenilin mutation associated with logopenia, disorientation, and apraxia in an autosomal-dominant Alzheimer's disease family (2020) (3)
- [Cost and quality aspects in the treatment of Parkinson's disease]. (2006) (3)
- Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective (2022) (3)
- A Quantitative View on Naturally Occurring Autoantibodies in Neurodegenerative Diseases (2018) (3)
- New version of the UPDRS: Development methods and working document for field testing (2005) (3)
- Parkinson Neuropsychometric Dementia Assessment (2017) (3)
- Parkinson's syndrome in a young patient with Klinefelter's syndrome —A case report (2008) (3)
- Psychometric Properties of an Abbreviated Version of the Apathy Evaluation Scale for Parkinson Disease (AES-12PD). (2018) (3)
- A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic "CERAD-Plus" tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study. (2021) (3)
- Comment: β-Amyloid pathology and Parkinson disease (2017) (2)
- Status of clinical research in neurology in Germany—A national survey (2021) (2)
- Reply: Cabergoline versus levodopa therapy (2004) (2)
- Diagnosis and treatment of Alzheimer's disease and other neurodegenerative diseases causing dementia (2008) (2)
- Antidepressant medication in a German cohort of patients with Alzheimer's disease . (2018) (2)
- PND38 COSTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GILLES DE LA TOURETTE'S SYNDROME (2009) (2)
- [Differences Between Self- and Proxy-Assessment of Health-Related Quality of Life in Patients with Mild Cognitive Impairment and Alzheimer's Disease]. (2017) (2)
- Quality of life and resource utilization‐Swedish data from the Care of Late‐Stage Parkinsonism (CLaSP) study (2022) (2)
- Dementia in Parkinson's disease (2004) (2)
- Lumbar dynamic pedicle-based stabilization versus fusion in degenerative disease: a multicenter, double-blind, prospective, randomized controlled trial. (2022) (2)
- Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
- Benchmarking in der Patientenversorgung: Depression bei Parkinson-Patienten (2011) (2)
- IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease (2018) (2)
- The Role of CNI-1493 in the function of primary microglia with respect to β-Amyloid (2011) (2)
- S33.01 - Human anti-prion protein antibodies block A117V PrP peptide fibril formation and prevent A117V PrP peptide-induced neurotoxicity (2008) (2)
- PHS50 Health Care Resource Use and Cost in Alzheimer's Disease in Three European Countries – Baseline Findings of the GERAS Study (2012) (2)
- Health-related Quality of Life in Patients with Sleep-Related Breathing Disorder (2017) (1)
- The Socioeconomic Impact of Narcolepsy NARCOLEPSY (2004) (1)
- Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β (2021) (1)
- PNL10 THE SOCIOECONOMIC IMPACT OF NARCOLEPSY (2004) (1)
- MIF (macrophage migration inhibitory factor (glycosylation-inhibiting factor)) (2011) (1)
- The Economic Impact of Restless Legs Syndrome (2007) (1)
- Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease [Neuroscience Letters 342 (2003) 132–134] (2003) (1)
- Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments (2021) (1)
- How Useful are Eq-5d And Zbi In Assessing The Impact of Caring for Alzheimer's Disease Patients? (2015) (1)
- Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia (2013) (1)
- [Towards a vaccine against Alzheimer's?]. (2013) (1)
- Lead exposure induces beta-amyloid accumulation and inhibits LRP1 expression in APP transgenic mice (2010) (1)
- Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning (2017) (1)
- [Inclusion Body Myopathy, Paget's Disease, and Fronto-temporal Dementia: a VCP-related Multi-systemic Proteinopathy]. (2018) (1)
- [Memory clinics in Germany-structural requirements and areas of responsibility]. (2020) (1)
- 5th International Conference on Neurology and Epidemiology. Gold Coast, Australia, November 18-20, 2015: Abstracts (2015) (1)
- An application of electronic nose technology for diagnosis of Alzheimer's disease (2013) (1)
- Benchmarking in der Patientenversorgung (2007) (1)
- Health-Related Quality of Life in Patients with Hypersomnia (2013) (1)
- Programme Démence Prévention (pdp ): A Nation-Wide Programme for Dementia Prevention in Luxembourg (2020) (0)
- P118 Health-related quality of life and disease-related costs in multiple system atrophy and progressive supranuclear palsy (2011) (0)
- PMD29 A MULTI-OUTCOME DECISION MODEL FOR PARKINSON'S DISEASE (2003) (0)
- Contents of Forthcoming Issues (2008) (0)
- [The Cost of Early Diagnosis of Cognitive Decline in German Memory Clinics]. (2022) (0)
- Economic burden and health-related quality of life in restless legs syndrome (2008) (0)
- [Dementia with Lewy bodies]. (2018) (0)
- P2-148 Decrease of mid-regional proenkephalin A and N-terminal protachykinin A immune reactivity in cerebrospinal fluid of patients with dementia and acute neuroinflammation (2006) (0)
- P.P.3 03 Macrophage migration inhibitory factor in normal skeletal muscle and inflammatory myopathies (2006) (0)
- Abstracts from the European Society for Medical Decision Making Meeting Rotterdam, the Netherlands, June 7-8, 2004 (2004) (0)
- Contents Vol. 66, 2011 (2011) (0)
- In-vitro mechanisms of action of naturally occurring autoantibodies against Aβ (2011) (0)
- [Early diagnosis of dementia]. (2020) (0)
- 2015 Annual Meetings. (2015) (0)
- Care of PD patients with dementia in office-based neurologists: a national Survey (GEPAD study) (2009) (0)
- PND14 COSTS OF ILLNESS IN PARKINSON'S DISEASE IN SIX EUROPEAN COUNTRIES (2009) (0)
- Contents Vol. 7, 2010 (2010) (0)
- Time-to-event Analysis for CER in Progressive Diseases: The Case of Parkinson's Disease. (2014) (0)
- O0025 The social cost of narcolepsy (2007) (0)
- Apathy in patients with Alzheimer's disease is a cost-driving factor. (2023) (0)
- Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease (2014) (0)
- PNL22 EFFECT OF DISEASE-SPECIFIC COMPLICATIONS ON THE PREDICTION OF UTILITIES IN PARKINSON'S DISEASE (2004) (0)
- PNL12 HEALTHCARE UTILIZATION AND SOCIOECONOMIC ASPECTS OF NEUROMUSCULAR DISEASES (2004) (0)
- Die German Study on the Epidemiology of Parkinson's Disease with Dementia (GEPAD): mehr als nur Parkinson (2010) (0)
- Health-related quality of life and pharmacotherapy in Parkinson's disease: results of a multi-country study of the EuroPA Study Group (2009) (0)
- Cardiac Arrest Center - New Structures to the optimized Post-Resuscitation Care (2015) (0)
- [Innovative treatment approaches for Alzheimer's disease. Immunotherapy]. (2008) (0)
- The choroid plexus is involved in antibody-induced beta-amyloid clearance (2009) (0)
- PNL3 PREDICTORS FOR DIRECT AND INDIRECT COSTS IN PARKINSON'S DISEASE (2004) (0)
- Meetings and Conferences · Tagungen und Kongresse (2009) (0)
- No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors (2019) (0)
- Within-family associations and disease progression in familial multiple sclerosis (2009) (0)
- LACK OF apoE GENE REDUCES AMYLOID FORMATION IN TRANSGENIC MICE OVEREXPRESSING APPV717F (1998) (0)
- Versorgung von Parkinson-Patienten in Europa. European Cooperative Network for research, diagnosis and the therapy of Parkinson's disease (EuroPa) (2004) (0)
- PNL25 INTERNAL, EXTERNAL, AND CROSS-MODEL VALIDATION OF A MULTI-OUTCOME DECISION MODEL FOR PARKINSON'S DISEASE (2004) (0)
- Etablierung eines Cardiac Arrest Center. Innovative Modellstrukturen zur Optimierung der Post-Reanimationsbehandlung (2016) (0)
- Cost of Illness in Subarachnoid Hemorrhage (2010) (0)
- NP4 12-MONTHS COSTS OF PARKINSON'S DISEASE IN GERMANY—RESULTS OF A PROSPECTIVE STUDY (2004) (0)
- Reply to letter: Projected numbers of people with movement disorders in the years 2030 and 2050: Implications for sub‐Saharan Africa, using essential tremor and Parkinson's disease in Tanzania as an example (2012) (0)
- FV 37 Cortical and subcortical volumetry in patients with Parkinsons disease and cognitive impairment (2019) (0)
- Factors influencing short-term functional recovery of geriatric hip fracture patients – a prospective observational study (2013) (0)
- PNL7 COSTS OF STROKE UNIT CARE IN GERMANY (2004) (0)
- Contents Vol. 37, 2011 (2011) (0)
- Passive immunization with natural occurring anti-abeta antibodies leads to differential effects on cognition in APP transgenic mice (2009) (0)
- In vivo detection of Alzheimer disease in APP transgenic mice with T 2-Mapping (2011) (0)
- Inflammatory markers as risk factor for the early stage (MCI) of Alzheimer's disease (2002) (0)
- Reply (2019) (0)
- V36 Health-related quality of life in patients with Parkinson’s disease in Europe: Multicenter study of the EuroPA Study Group (2011) (0)
- [The costs of epilepsy in Germany]. (2007) (0)
- PNM1 CARE OF PARKINSON'S DISEASE PATIENTS IN EUROPEAN COUNTRIES; EUROPEAN COOPERATIVE NETWORK FOR RESEARCH, DIAGNOSIS AND, THERAPY OF PARKINSON'S DISEASE (EUROPA) (2003) (0)
- [Dementia: relevant aspects for otorhinolaryngologists]. (2020) (0)
- PNL21 INDEPENDENT EFFECT OF DYSKINESIA ON HEALTHRELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE—A MULTIVARIATE ANALYSIS (2004) (0)
- Progressive Loss of Cardiac Sympathetic Innervation in Parkinson’s Disease (2002) (0)
- QL2 THE HEALTH RELATED QUALITY OF LIFE IN PARKINSON'S DISEASE IN GERMANY (2004) (0)
- BUPROPION FOR THE TREATMENT OF APATHY IN ALZHEIMER’S DISEASE: A MULTICENTER RANDOMIZED CONTROLLED TRIAL (2019) (0)
- Subject Index Vol. 75, 2008 (2008) (0)
- PMH51 HEALTH STATUS AND COST OF CARE IN PATIENTS WITH DEMENTIA IN GERMANY (2010) (0)
- P4-073 CDC2 gene polymorphism is associated with cognitive decline in Alzheimer's disease (2004) (0)
- Individual and Societal Impact (2013) (0)
- SINGLE IMMUNIZATION WITH HUMAN NATURALLY OCCURRING AUTOANTIBODIES AGAINST BETA AMYLOID AFTER 24 H LEADS TO ENHANCED SYNAPTOPHYSIN IMMUNOREACTIVITY AND RESTORES COGNITIVE DEFICITS IN TG 2576 MICE (2011) (0)
- ND2: ASSESSING THE QUALITY OF LIFE IN PARKINSON'S DISEASE (2001) (0)
- Contents Vol. 8, 2011 (2011) (0)
- The Paroxysmal Disorders (2011) (0)
- PR1 A LATENT GENERAL GROWTH MIXTURE MODEL FOR HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON DISEASE ACROSS 36 MONTH (2009) (0)
- P131 Influence of the naturally occurring α-synuclein-antibody on toxic α-synuclein-fragments (2011) (0)
- P3-279 MIF contributes to inflammation in the Alzheimer’s disease brain (2006) (0)
- IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker Disease (2018) (0)
- Klinefelter syndrome and parkinsonism (2007) (0)
- PHS92 Allocation of Research Funding in Health Care in Relation to Disease Burden in Europe (2012) (0)
- PNL24 COMPARING CLASSIFICATION AND REGRESSION TREE ANALYSIS WITH MULTIPLE REGRESSION FOR TRANSLATING A CLINICAL PARKINSON'S DISEASE SCALE INTO UTILITIES (2004) (0)
- Reducing sample complexity of polyclonal human autoantibodies by chromatofocusing. (2010) (0)
- Contents Vol. 75, 2008 (2008) (0)
- P2-291: Administration of CNI-1493 inhibits Aβ accumulation, Amyloid plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease (2008) (0)
- PCV48 COST-OF-ILLNESS AND HEALTH-RELATED QUALITY OF LIFE IN SUBARACHNOID HEMORRHAGE: GERMAN LONGITUDINAL STUDY (2010) (0)
- The influence of myocardial infarction and stroke on patient related quality of life (2008) (0)
- Direct and indirect costs of epilepsy in a tertiary epilepsy centre in Germany (2006) (0)
- The anti-inflammatory drug CNI-1493 regulates the intracellular processing of Aβ in different cell types of the brain (2009) (0)
- α 1-antitrypsin modulates microglial-mediated neuroinflammation and protects microglial cells from amyloid-β-induced toxicity (2014) (0)
- P2-149 Procalcitonin in cerebrospinal fluid is elevated in patients with dementia and acute neuroinflammation (2006) (0)
- [Multimorbidity: a central challenge for modern medicine]. (2014) (0)
- FV 36 Cognitive deficits and microstructural correlates in Parkinsons disease: DTI data from the LANDSCAPE study (2019) (0)
- GENTAMICIN-INDUCED OTOTOXICITY BY NHIBITING p 38 MAP KINASE PHOSPHORYLATION AND CASPASE 3 CTIVATION (2005) (0)
- PMD33 THE USE OF A SEMI-MARKOV PROCESS MODEL IN COST-EFFECTIVENESS MODELING: THE CASE OF ANTI-EPILEPTIC DRUGS (2010) (0)
- Longitudinal Study on Functional and Cognitive Outcomes in Patients with Postoperative Delirium after Femoral Fracture (2019) (0)
- Characterizing the individual course of health-related quality of life after subarachnoid haemorrhage: Latent growth mixture modelling. (2023) (0)
- Brain glucose metabolism in patients with mild to moderate Alzheimer's disease before and after six months treatment with intravenous immunoglobulin (octagam 10%): A phase II double blind, placebo-controlled multi-center study (2011) (0)
- Compounds in exhaled air for the detection of Alzheimer's disease (2013) (0)
- Contents Vol. 45, 2015 (2015) (0)
- V35 The cost-effectiveness of deep brain stimulation for Parkinson's disease (2011) (0)
- P4-107 A genetic variation of the interleukin-1 receptor agonist reduces the risk for late onset sporadic Alzheimer's disease (2004) (0)
- The costs of sleep related breathing disorders: a prospective, representative study in the German state of Hessen (2013) (0)
- [Benchmarking in patient care: depression in Parkinson's disease]. (2011) (0)
- Single immunization with human naturally occurring autoantibodies against beta amyloid after 24 h leads to enhanced synapse formation and restores cognitive deficits in Tg2576 mice (2011) (0)
- P4-226 C/T conversion affects interleukin 1A promoter function in a human astrocyte cell line (2004) (0)
- PND6: ASSESSING THE COSTS OF PARKINSON'S DISEASE IN GERMANY (2001) (0)
- [Parkinson's disease and Alzheimer type dementia-Pathophysiology and drug treatment approaches]. (2023) (0)
- PND23 HEALTH ECONOMIC EVALUATION OF LAMOTRIGINE VERSUS LEVETIRACETAME IN THE INITIAL MONOTHERAPY OF EPILEPSY LALIMO-TRIAL) (2009) (0)
- P1-100 CNI-1493 inhibits Aβ production and prevents plaque formation in an animal model of Alzheimer’s disease (2006) (0)
- Measurements of Costs and Scales for Outcomes in Health Economic Studies of Parkinson’s Disease (2012) (0)
- PND3: COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PATIENTS WITH PARKINSON'S DISEASE (2001) (0)
- P130 Heat shock protein 60 and toll like receptor 4 as an endogenous activator complex of microglia in Parkinson disease (2011) (0)
- Subject Index Vol. 7, 2010 (2010) (0)
- New version of the UPDRS (MDS-UPDRS): Factor analysis (2008) (0)
- Randomized double-blind placebo-controlled dose-finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer's disease (2010) (0)
- FV4 Brain atrophy distribution and rate of change in patients with advanced Parkinsons disease and cognitive impairment (2020) (0)
- PMD31 DECISION-ANALYTIC MODELING IN PARKINSON'S DISEASE (2003) (0)
- Author Correction: Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease (2023) (0)
- PMS23 COST OF ILLNESS IN AMYOTROPHIC LATERAL SCLEROSIS, MYASTHENIA GRAVIS AND FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (2009) (0)
- bcl-2 Protects SK-N-SH Cells From 6-Hydroxydopamine Induced Apoptosis by Inhibition of Cytochrome c Redistribution (2000) (0)
- Economic Evaluations of Treatment Options in Patients with Alzheimer's Disease – A Systematic Review (2011) (0)
- The MAP kinase inhibitor drug CNI-1493 leads to cognitive improvement in an animal model of AD after 24 hours (2011) (0)
- PNL28 CENTERED REGRESSION FUNCTIONS AS A TECHNIQUE TO IMPROVE FLEXIBILITY AND TRANSFERABILITY OF MARKOV MODELS (2004) (0)
- PND17 THE COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE PATIENTS (2009) (0)
- PND48 Health State Values in Alzheimer'S Disease – Baseline Results From a Large Prospective Observational Study in Three European Countries (GERAS) (2012) (0)
- NPI HEALTH-RELATED QUALITY OF LIFE IN NEUROMUSCULAR DISEASES (2004) (0)
- S4-01-04 Abeta-antibodies in serum and CSF as potential marker of biological activity in AD (2006) (0)
- Specificity Of The Anti-inflammatory Drug Cni-1493 Over Amyloid Beta Species And The Cell Type (2009) (0)
- Cost of illness of apathy in Alzheimer’s disease (2021) (0)
- Activation of SK3/K(Ca)2.3 channels modulate the response of LPS-stimulated microglial cells (2012) (0)
- The Anti-inflammatory Drug Cni-1493 Decreases The Toxic Amyloid Oligomers And Induces Neuro-protective Effect In App Transgenic Mice (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Richard C. Dodel?
Richard C. Dodel is affiliated with the following schools:
